¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"relative risk"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 9 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • relative metabolic rate
    »ó´ë´ë»çÀ²
  • relative motion
    »ó´ë¿îµ¿
  • relative odds
    »ó´ëÀû´ëÀÀºñ
  • relative refractory period
    »ó´ëºÒÀÀ±â
  • relative scotoma
    »ó´ë¾ÏÁ¡
  • relative sterility
    »ó´ëÀûºÒÀÓ
  • relative survival rate
    »ó´ë»ýÁ¸À²
  • relative valvular insufficiency
    »ó´ëÀûÆÇ¸·±â´ÉºÎÀü
  • resource based relative value scale
    ÀÚ¿ø±âÁØ»ó´ë°¡Ä¡µî±Þ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • attributable risk
    ±â¿©À§Çèµµ
  • risk assessment
    À§ÇèµµÆò°¡
  • risk benefit analysis
    À§ÇèÆíÀͺм®
  • behavioral risk factor
    ÇൿÀ§Çè¿äÀÎ
  • benefit/risk ratio
    À¯ÀÍÀ¯ÇغñÀ²
  • radiation risk coefficient
    ¹æ»ç¼±À§ÇèÁö¼ö
  • risk difference
    À§ÇèµµÂ÷ÀÌ
  • explosion risk
    Æø¹ßÀ§Çèµµ
  • risk factor
    À§ÇèÀÎÀÚ
  • high risk group
    °íÀ§Çèµµ±º
  • lifetime risk
    Æò»ýÀ§Çèµµ
  • multiple risk
    ´ÙÁßÀ§Çèµµ
  • risk management
    À§Çèµµ°ü¸®
  • risk marker
    À§Ç赵ǥÁö
  • operative risk
    ¼ö¼úÀ§Çèµµ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • relative dullness
    °æÅ¹À½°è(ÌîöúëåÍ£)
  • relative error
    »ó´ë¿ÀÂ÷(Ë×ËÀËí̤).
  • relative field
    ºñ±³¿µ¿ª(ÝïÎòçÐæ´).
  • relative flatness
    »ó´ëŹÀ½
  • relative frequency
    ºñ±³ºóµµ(ËÓË´Ë×̬).
  • relative growth
    »ó´ëÀû »ýÀå(ßÓÓßîÜßæíþ)
  • relative hearing
    »ó´ë(Àû) û°¨
  • relative hepatic dullness
    »ó´ë°£Å¹À½°è(ßÓÓßÊÜöúëåÍ£).
  • relative hepatic dullness
    »ó´ë°£Å¹À½°è(ßÓÓßÊÜöúëåÍ£)
  • relative humidity
    »ó´ë½Àµµ
  • relative immunity
    »ó´ë¸é¿ª(¡­Øóæ¹).
  • relative incompetence
    »ó´ë¼º ºÎÀü(¡­àõÝÕîï).
  • relative incompetence
    »ó´ë¼º ºÎÀü(ßÓÓßàõÝÕîï)
  • relative leukocytosis
    ºñ±³¹éÇ÷±¸Áõ°¡Áõ(ÝïÎòÛÜúìϹñòÊ¥ñø).
  • relative leukocytosis
    ºñ±³¹éÇ÷±¸Áõ°¡Áõ(ÝïÎòÛÜúìϹñòÊ¥ñø)
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • relative afferent pupillary defect
    »ó´ëÀû±¸½É¼ºµ¿°ø¿îµ¿Àå¾Ö
  • relative biologic effectiveness of radiation
    ¹æ»ç¼±ÀÇ»ó´ëÀû»ý¹°ÇÐÀûÈ¿°ú(Û¯ÞÒàÊ¡­ßÓÓßîÜßæÚªùÊîÜüùÍý)
  • relative biological effectiveness
    »ó´ë»ý¹°ÇÐÀûÈ¿°ú
  • relative biological effectiveness
    »ó´ëÀû »ý¹°ÇÐÀû È¿°ú(ßÓÓßîÜßæÚªùÊîÜüù
  • relative cardiac dullness
    »ó´ë½ÉŹÀ½°è(ßÓÓßãýöúëåÍ£).
  • relative cardiac dullness
    »ó´ë½ÉŹÀ½°è(ßÓÓßãýöúëåÍ£)
  • relative centrifugal force
    »ó´ë¿ø½É·Â(ßÓÓßêÀãýæ³).
  • relative centrifugal force
    ºñ¿ø½É·Â.
  • relative convergence
    »ó´ëÆøÁÖ(ÝïÎòÜßñÍ), »ó´ë´«¸ðÀ½
  • relative dispersion
    »ó´ëºÐ»ê(ßÓÓßÝÂߤ).
  • relative divergence
    ºñ±³°³»ê(ÝïÎòËÒߤ).
  • relative dose
    ºñ±³ Á¶»ç·®
  • relative dullness
    °æÅ¹À½°è(ÌîöúëåÍ£).
  • relative dullness
    °æÅ¹À½°è(ÌîöúëåÍ£)
  • relative error
    »ó´ë¿ÀÂ÷(Ë×ËÀËí̤).
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
ASHCRM American Society of Health Care Risk Managers
CDC-BRFS Centers for Disease Control Behavioral Risk Factor Survey
CDSRF chronic disease and sociodemographic risk factors
CSPINE corticosteroid use, seropositive RA, peripheral joint destruction, involvement of cervical nerves, n...
DRC damage risk criterion; dendritic reticulum cell; diagnostic reporting console; digitorenocerebral [s...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
BRFSS Behavioral Risk Factor Surveillance System
CVRF Cardiovascular risk factor
CRIB Clinical Risk Index for Babies
CARDIA Coronary Artery Risk Development In Young Adults
CORIS Coronary Risk Factor Study
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 12 ÆäÀÌÁö: 3
risk factors An aspect of personal behaviour or lifestyle, environmental exposure, or inborn or inherited characteristic, which, on the basis of epidemiologic evidence, is known to be associated with a health-related condition considered important to prevent.
(12 Dec 1998)
risk management The process of minimizing risk to an organization by developing systems to identify and analyze potential hazards to prevent accidents, injuries, and other adverse occurrences, and by attempting to handle events and incidents which do occur in such a manner that their effect and cost are minimised. Effective risk management has its greatest benefits in application to insurance in order to avert or minimise financial liability.
(12 Dec 1998)
risk of recurrence In medical genetics, the chance that a genetic (inherited) disease present in a family will recur in that family. The concept in general medicine means the chance that an illness we come back again.
(12 Dec 1998)
risk patient Patient who is at risk, because of his/her behaviour or because of the type of person he/she is.
(18 Nov 1997)
risk reduction Techniques used to reduce your chances of getting a certain cancer. For example: reducing your dietary fat may help prevent breast cancer.
(09 Oct 1997)
risk-taking Undertaking a task involving a challenge for achievement or a desirable goal in which there is a lack of certainty or a fear of failure. It may also include the exhibiting of certain behaviours whose outcomes may present a risk to the individual or to those associated with him or her.
(12 Dec 1998)
competing risk An event that removes a subject from being at risk for an outcome under investigation.
(05 Mar 2000)
pregnancy, high-risk Pregnancy in which the mother and/or foetus are at greater than normal risk of morbidity or mortality. Causes include lack of adequate prenatal care, previous obstetrical history, pre-existing maternal disease or pregnancy-induced disease, and multiple gestation, as well as advanced maternal age.
(12 Dec 1998)
health risk assessment Method of describing an individual's chance of falling ill or dying of a specified condition, based on actuarial calculations that allow for known exposure to risk; expressed as expected age at which death or disease will occur, and intended as a way of drawing an individual's attention to the probable consequences of risk behaviour.
(05 Mar 2000)
oesophageal carcinoma risk factors <radiology> P Plummer-Vinson Web, A achalasia, alcohol, B Barrett oesophagus, S stricture, T tylosis, tobacco see: oesophageal carcinoma
(12 Dec 1998)
thyroid carcinoma risk factors <radiology> Increased risk of malignancy: young female, male, history of radiation to head or neck, hard lesion, other neck masses, no shrinkage on TSH, family hx of thyroid carcinoma see: thyroid carcinoma
(12 Dec 1998)
empiric risk The chance that a disease will occur in a family based upon experience (past history, medical records, etc.) rather than theory.
(12 Dec 1998)
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
relative risk The risk of getting a disease in a group with the risk factor divided by the risk of getting a disease in a group without the risk factor.
Ãâó: www.etr.org/recapp/research/researchglossary.htm
relative risk (RR): the ratio of the probability of developing, in a specified period of time, an outcome among those receiving the treatment of interest or exposed to a risk factor, compared with the probability of developing the outcome if the risk factor or intervention is not present.
Ãâó: www.cefpas.it/ebm/tools/glossary.htm
relative risk The ratio of the risk of disease or death among the exposed to the risk among the unexposed.
Ãâó: beta.austlii.edu.au/au/other/IndigLRes/1991/8/
relative risk A woman's risk of developing breast cancer compared to women who do not have the same risk factors. If you hear a report stating that "breast cancer was found to be increased 10-fold... or by 76%... or 5 times as common" you are listening to relative risks.
Ãâó: www.thinprep.com/women/women_breast_cancer_glossar...
relative risk It is the risk "related" to an exposure, characteristic, or habit compared to the risk existing in those without the exposure, characteristic, or habit. It is a measure of the strength of the association of a risk factor or exposure with the disease.
Ãâó: startwithyourheart.com/glossary.htm
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
ÅëÇÕ°Ë»ö ¿Ï·á